Interaction Checker
Potential Interaction
Dolutegravir/Lamivudine (DTG/3TC)
Rifampicin (Rifampin)
Quality of Evidence: Very Low
Summary:
Coadministration with Dovato (dolutegravir/lamivudine) has not been studied. The dolutegravir dose (50 mg) in Dovato is insufficient when coadministered with certain drugs, such as rifampicin, that may decrease dolutegravir concentrations. The European and US product labels for Dovato recommend that an additional 50 mg tablet of dolutegravir, separated by 12 hours from Dovato, should be taken. This dose adjustment should be maintained for approximately 2 weeks after stopping rifampicin as the inducing effect may persist after discontinuation of a strong inducer. Coadministration of rifampicin (600 mg once daily) and twice daily dolutegravir (50 mg twice daily) decreased dolutegravir Cmax, AUC and Ctrough by 43%, 54% and 72%, respectively, compared to twice daily dolutegravir alone. When coadministration of these doses was compared to once daily dolutegravir (50 mg once daily), dolutegravir Cmax, AUC and Ctrough increased by 18%, 33% and 22%, respectively. A modelling study showed that this dose adjustment is also sufficient in individuals with a high BMI. Considering the limited experience when coadministering inducers with dual antiretroviral regimens, close monitoring of HIV infection is recommended. Further studies are required as to whether administering dolutegravir once daily at a dose of 100 mg can mitigate the reduction in dolutegravir exposure seen with rifampicin. The interaction between lamivudine and rifampicin is unlikely to be of clinical significance. Estimated population pharmacokinetic parameters for lamivudine during and after rifampicin were similar once between-occasional variability in bioavailability and absorption rate constant were accounted for. Of note: a high dose of rifampicin (35 mg/kg) compared to the standard dose (10 mg/kg) resulted in 43% decrease in dolutegravir trough concentrations (0.46 mg/L vs 0.80 mg/L). Most patients had dolutegravir concentrations above the IC90 target (0.064 mg/L), however, a higher proportion of participants on higher dose rifampicin failed to attain the 0.3 mg/L target. Importantly, no patient below either target thresholds had a detectable HIV viral load at week 24.
Description:
View all available interactions with Dolutegravir/Lamivudine (DTG/3TC) by clicking here.
Copyright © 2026 The University of Liverpool. All rights reserved.